Exhibit 5.1

 

 

1271 Avenue of the Americas |New York, NY 10020

blankrome.com

 

February 14, 2022

 

Adial Pharmaceuticals, Inc.

1180 Seminole Trail, Ste 495
Charlottesville, VA 22901

 

Re: Adial Pharmaceuticals, Inc.
Registration Statement on Form S-3 and Related Prospectus Supplement

 

Dear Sir/Madam:

 

We have acted as counsel to Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with a final prospectus supplement, dated February 10, 2022 (the “Prospectus Supplement”) to the base prospectus (the “Base Prospectus”) that forms a part of the Registration Statement on Form S-3 (Registration No. 333-237793) (the “Registration Statement”) filed by the Company on April 22, 2020 under the Securities Act of 1933, as amended (the “Act”), with the U.S. Securities and Exchange Commission (the “Commission”), and declared effective on April 30, 2020, relating to the public offering of 2,322,250 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,865,000 shares of Common Stock (the “Pre-Funded Warrant Shares”).

 

In our capacity as counsel to the Company, we have examined the original or certified copies of such records of the Company and such agreements, certificates of public officials, certificates of officers or representatives of the Company and others, and such other documents as we deem relevant and necessary as a basis for the opinions hereinafter expressed. In such examination we have assumed the genuineness of all signatures on original documents and the conformity to original documents of all copies submitted to us as conformed or photostat copies. As to various questions of fact material to such opinions, we have relied upon statements or certificates of officials and representatives of the Company and others.

 

Based upon the foregoing, it is our opinion that:

 

1.The shares of Common Stock, when sold, paid for and issued, will be duly and validly issued, fully paid and non-assessable.

 

2.When the Pre-Funded Warrants are sold, paid for and issued, will be the valid and binding obligations of the Company.

 

3.The Pre-Funded Warrant Shares issuable upon exercise of the Pre-Funded Warrants, when sold, paid for and issued upon exercise of the Pre-Funded Warrants and upon receipt of payment of the exercise price thereof, if applicable, in accordance with the respective terms thereof, will be duly and validly issued, fully paid and non-assessable.

 

We are opining solely on all applicable statutory provisions of Delaware corporate law, including the rules and regulations underlying those provisions, all applicable provisions of the Delaware Constitution and all applicable judicial and regulatory determinations. This opinion is limited to the laws of the State of Delaware as in effect on the date hereof and we express no opinion with respect to the laws of any other jurisdiction. We hereby consent to the filing of this opinion as an Exhibit to the Registration Statement. We also hereby consent to the use of our name as your counsel under “Legal Matters” in the Prospectus Supplement constituting part of the Registration Statement. In giving this consent, we do not thereby concede that we come within the categories of persons whose consent is required by the Act or the General Rules and Regulations promulgated thereunder.

 

  Very truly yours,  
     
  /s/ BLANK ROME  
     
  BLANK ROME LLP  

 

 

 

 

 

Blank Rome LLP | blankrome.com